News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cortice Biosciences Announces Enrollment Of A Clinical Trial Targeting Tau Dysfunction In Mild-To-Moderate Alzheimer's Disease



1/22/2014 8:57:47 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK, Jan. 21, 2014 (GLOBE NEWSWIRE) -- Cortice Biosciences announced today that enrollment has begun in a Phase 1 open-label dose-escalation trial designed to evaluate safety, tolerability and preliminary efficacy of the company's lead drug candidate, TPI 287, for treatment of patients with mild-to-moderate Alzheimer's disease (www.clinicaltrials.gov ID NCT01966666). TPI 287 is an abeotaxane, a taxoid that binds to and stabilizes microtubules (MTs) similarly to the taxanes, paclitaxel and docetaxel. A distinct advantage of TPI 287 over the taxanes is an ability to readily cross the blood-brain barrier.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES